The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis
Abstract
High-density tissue microarrays (TMA) are useful for profiling protein expression in a large number of samples but their use for clinical biomarker studies may be limited in heterogeneous tumors like prostate cancer. In this study, the optimization and validation of a tumor sampling strategy for a prostate cancer outcomes TMA is performed. Prostate cancer proliferation determined by Ki-67 immunohistochemistry was tested. Ten replicate measurements of proliferation using digital image analysis (CAS200, Bacus Labs, Lombard, IL, USA) were made on 10 regions of prostate cancer from a standard glass slide. Five matching tissue microarray sample cores (0.6 mm diameter) were sampled from each of the 10 regions in the parallel study. A bootstrap resampling analysis was used to statistically simulate all possible permutations of TMA sample number per region or sample. Statistical analysis compared TMA samples with Ki-67 expression in standard pathology immunohistochemistry slides. The optimal sampling for TMA cores was reached at 3 as fewer TMA samples significantly increased Ki-67 variability and a larger number did not significantly improve accuracy. To validate these results, a prostate cancer outcomes tissue microarray containing 10 replicate tumor samples from 88 cases was constructed. Similar to the initial study, 1 to 10 randomly selected cores were used to evaluate the Ki-67 expression for each case, computing the 90th percentile of the expression from all samples used in each model. Using this value, a Cox proportional hazards analysis was performed to determine predictors of time until prostate-specific antigen (PSA) recurrence after radical prostatectomy for clinically localized prostate cancer. Examination of multiple models demonstrated that 4 cores was optimal. Using a model with 4 cores, a Cox regression model demonstrated that Ki-67 expression, preoperative PSA, and surgical margin status predicted time to PSA recurrence with hazard ratios of 1.49 (95% confidence interval [CI] 1.01-2.20, p = 0.047), 2.36 (95% CI 1.15-4.85, p = 0.020), and 9.04 (95% CI 2.42-33.81, p = 0.001), respectively. Models with 3 cores to determine Ki-67 expression were also found to predict outcome. In summary, 3 cores were required to optimally represent Ki-67 expression with respect to the standard tumor slide. Three to 4 cores gave the optimal predictive value in a prostate cancer outcomes array. Sampling strategies with fewer than 3 cores may not accurately represent tumor protein expression. Conversely, more than 4 cores will not add significant information. This prostate cancer outcomes array should be useful in evaluating other putative prostate cancer biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationPrognostic Factors in Prostate Cancer: College of American Pathologists Consensus Statement 1999
Bostwick, D. G., Grignon, D. J., Hammond, M. E. H., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montironi, R., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0995-pfipc · Cited by 1,239
Classification of prostatic carcinomas.
Gleason, D. F. (1966) · PubMed · Cited by 1,110
Hoos, A., Urist, M. J., Stojadinovic, A., Mastorides, S., Dudas, M. E., Leung, D. H. Y., Kuo, D., Brennan, M. F., Lewis, J. J., & Cordon-Cardo, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64075-8 · Cited by 400
Nocito, A., Bubendorf, L., Tinner, E. M., Süess, K., Wagner, U., Forster, T., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., et al. (2001) · The Journal of Pathology · doi:10.1002/1096-9896(200107)194:3<349::aid-path887>3.0.co;2-d · Cited by 317
Mucci, N. R., Akdas, G., Manely, S., & Rubin, M. A. (2000) · Human Pathology · doi:10.1053/hp.2000.7295 · Cited by 182
Self-citationKi-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt, M., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G. R., & Moul, J. W. (1996) · PubMed · Cited by 150
Ki-67 Expression is a Prognostic Marker of Prostate Cancer Recurrence after Radical Prostatectomy
Bettencourt, M., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., & Moul, J. W. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)65703-3 · Cited by 128
Cited by
Nanotechnology applications in cancer
Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.152025 · Cited by 952
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Self-citationMehra, R., Tomlins, S. A., Shen, R., Nadeem, O., Wang, L., Wei, J. T., Pienta, K. J., Ghosh, D., Rubin, M. A., Chinnaiyan, A. M., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800769 · Cited by 303
Self-citationRhodes, D. R., Sanda, M. G., Otte, A. P., Chinnaiyan, A. M., & Rubin, M. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.661 · Cited by 271
Self-citationMorrison, C., Zanagnolo, V., Ramirez, N., Cohn, D. E., Kelbick, N., Copeland, L., Maxwell, L. G., & Fowler, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4827 · Cited by 258
Metadata
- Authors
- Rubin, M. A., Dunn, R., Strawderman, M., & Pienta, K. J.
- Venue
- The American Journal of Surgical Pathology
- Published
- 2002-03
- Volume
- 26
- Issue
- 3
- Pages
- 312-319
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W1988336550
- Cited by
- 318
- References
- 13
- FWCI
- 22.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis. https://app.cochat.ai/papers/10.1097/00000478-200203000-00004
- The paper
- Rubin, M. A., Dunn, R., Strawderman, M., & Pienta, K. J. (2002). Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis. The American Journal of Surgical Pathology. https://doi.org/10.1097/00000478-200203000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.